These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 30257416)

  • 1. Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in
    Xiong C; Mao Y; Wu T; Kang N; Zhao M; Di R; Li X; Ji X; Liu Y
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secretory expression of a bispecific antibody targeting tumor necrosis factor and ED-B fibronectin in Pichia pastoris and its functional analysis.
    Liu MY; Hu XP; Xie M; Jiang SJ; Li LJ; Liu DX; Yang XS
    Biotechnol Lett; 2014 Dec; 36(12):2425-31. PubMed ID: 25129049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
    Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
    Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
    Sun ZJ; Wu Y; Hou WH; Wang YX; Yuan QY; Wang HJ; Yu M
    Oncotarget; 2017 Apr; 8(17):29067-29079. PubMed ID: 28404966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
    Rabenhold M; Steiniger F; Fahr A; Kontermann RE; Rüger R
    J Control Release; 2015 Mar; 201():56-67. PubMed ID: 25617725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
    Wu Y; Yu M; Sun Z; Hou W; Wang Y; Yuan Q; Mo W
    Protein Pept Lett; 2018 Feb; 24(12):1105-1112. PubMed ID: 29046141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning, expression, purification and characterization of a bispecific single-chain diabody against fluoroquinolones and sulfonamides in Escherichia coli.
    Chen M; Wen K; Tao X; Xie J; Wang L; Li Y; Ding S; Jiang H
    Protein Expr Purif; 2014 Aug; 100():19-25. PubMed ID: 24816423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
    Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
    MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
    Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
    Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
    [No Abstract]   [Full Text] [Related]  

  • 16. Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells.
    Asano R; Kuroki Y; Honma S; Akabane M; Watanabe S; Mayuzumi S; Hiyamuta S; Kumagai I; Sode K
    MAbs; 2018; 10(6):854-863. PubMed ID: 29985753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.
    Cui X; Jia H; Xin H; Zhang L; Chen S; Xia S; Li X; Xu W; Chen X; Feng Y; Wei X; Yu H; Wang Y; Zhan Y; Zhu X; Zhang X
    Front Immunol; 2021; 12():778978. PubMed ID: 34925354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
    Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
    Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.
    Erdag B; Balcioglu BK; Bahadir AO; Serhatli M; Kacar O; Bahar A; Seker UO; Akgun E; Ozkan A; Kilic T; Tamerler C; Baysal K
    Biotechnol Appl Biochem; 2011; 58(6):412-22. PubMed ID: 22172104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.